Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types

H. van der Wijngaart, L.R. Hoes, J.M.V. Henegouwen, D.L. van der Velden, L.J. Zeverijn, P. Roepman, E. van Werkhoven, W.W.J. de Leng, A.M.L. Jansen, N. Mehra, D.G.J. Robbrecht, M. Labots, D.J.A. de Groot, A. Hoeben, P. Hamberg, H. Gelderblom, E.E. Voest, H.M.W. Verheul*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)6106-6114
Number of pages9
JournalClinical Cancer Research
Volume27
Issue number22
DOIs
Publication statusPublished - 1 Nov 2021

Keywords

  • HOMOLOGY-DIRECTED REPAIR
  • OVARIAN-CANCER
  • MAINTENANCE THERAPY
  • 2-STAGE DESIGNS
  • BREAST-CANCER
  • DOUBLE-BLIND
  • RISKS
  • MULTICENTER
  • SENSITIVITY
  • VALIDATION

Cite this